Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGN

Core Viewpoint - A class action lawsuit has been filed against Vistagen Therapeutics, Inc. for alleged violations of securities laws, specifically related to misleading statements about the results of its PALISADE-2 trial of fasedienol [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from April 1, 2024, to December 16, 2025, with a deadline for lead plaintiff appointments set for March 16, 2026 [2]. - The complaint alleges that Vistagen made false and misleading statements regarding the success of its drug candidate, creating a false impression of a successful Phase 3 trial [2]. Group 2: Investor Participation - Shareholders who purchased shares during the class period are encouraged to contact the law firm for potential lead plaintiff appointments, although such an appointment is not necessary to participate in any recovery [2][3].